Journal CANCERS (MDPI, Q1, IF 6.6) has announced special issue covering the topic of our symposium!
Special Issue “Chronic viral infections and cancer, openings for vaccines”
We are pleased to inform you that the website of Special Issue of CANCERS (MDPI, Q1,
IF 6.6) covering our symposium has been created and opened for submissions
Special Issue Editors
Dr. Maria Isaguliants
Guest Editor email@example.com
Riga Stradins University, Riga, Latvia
Interests: chronic viral infections and associated cancer; human immunodeficiency virus type 1; human hepatitis C virus; oxidative stress; T cell response; B cell response; DNA vaccines.Special Issue Information
Dr. Alexander Ivanov
Guest Editor firstname.lastname@example.org
Englelhard Institute of Molecular Biology, Moscow, Russia
Interests: hepatitis C virus; hepatitis delta virus; oncolytic viruses; reactive oxygen species; S-glutathionylation; polyamines; urea cycle; proline metabolism.
Prof. Franco M. Buonaguro
Guest Editor email@example.com
Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori – IRCCS Fondazione Pascale, Napoli, Italy
Interests: oncology; molecular biology; virology; biochemistry, peptide vaccines.
Special Issue Information
Approximately one out of eight human cancers has a viral etiology. Viral cancers open unique opportunities for both prophylaxis, diagnosis, and therapy, demonstrated by the success of HBV and HPV vaccines as well as HCV antivirals in decreasing the incidence of tumors associated with these infections.
For other chronic viral infections and associated cancers, problems still dominate over the progress. Prophylactic HPV vaccination does not cure already established infections, although an adjuvant role has been identified following conventional treatment, urgently requesting development of therapeutic HPV vaccines. Several are in pipeline, but still far from actual application for treatment of HPV-related cancers. Development of HCV vaccines is in progress, but is hampered by HCV variability and absence of longitudinal sterilizing anti-viral response. The success of antiretroviral therapy in controlling HIV-1 replication and immune reconstitution did not lead to significant reduction of HIV-1 associated cancers indicating alternative mechanisms of their development, not connected to immune suppression, requiring in-depth study and clinical interventions.
In this special issue we aim to unravel the progress in the studies of the molecular pathogenesis of chronic viral infections and cover the common mechanisms of action of human oncogenic viruses, such as the activity of viral oncoproteins, the induction of genomic instability, the support of chronic inflammation, and the modulation of tumor microenvironment. Special attention will be devoted to virus-induced alterations in the functions of immune system, to induction of innate and adaptive immune responses, including the relationship between the immune response to viral infections, metabolism and immunometabolism, as well as to oncolytic viruses. In-depth understanding of these processes would create new openings for the design of novel viral vaccines and immunotherapies.
Special invitation to submit is addressed to the participants of the international symposium “Chronic viral infections and cancer, openings for vaccines” held on-line December 16-17, 2021 www.techvac.org. sponsored by CANCERS.
Dr Maria Isaguliants
Dr Alexander Ivanov
Prof Franco M. Buonaguro
Chronic viral infection
High risk human papilloma viruses
Epstein Barr virus
Human hepatitis C virus
Human hepatitis B virus
Human hepatitis D virus
Human immunodeficiency virus type I
Animal models of chronic viral infections and cancer